Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Refractory Multiple Myeloma Clinical Trial

— Iber-KDd  

Official title:

Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05896228
• Other study ID #: 20230227
• Status: Recruiting
• Phase: Phase 2
• Start date: February 20, 2024
• Est. completion date: March 1, 2031

Study information

• Verified date: February 2024
• Source: University of Miami
• Contact: Michelle D Armogan
• Phone: 305-243-7479
• Email: mda182[@]med.miami.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: March 1, 2031
• Est. primary completion date: March 1, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients with histologically confirmed MM with progressive disease according to the IMWG criteria 47 during or within 60 days of their last regimen who have received 1-3 lines of prior therapy (inclusive of a lenalidomide-containing regimen) and have measurable disease within 4 weeks of enrollment based on one of the following:

• Serum monoclonal protein = 1.0 g/dL

• Urine monoclonal protein = 200 mg/24 hour

• Involved serum immunoglobulin free light chains (FLC) = 10 mg/dL AND abnormal kappa/lambda ratio.

Note: Because the primary endpoint is MRD-negativity rate, per the discretion of the Principal Investigator (PI), patients without measurable disease (e.g., M-spike < 1.0 g/dL) may also be enrolled in line with the IMWG MM response criteria 47.

2. Prior treatment with cluster of differentiation 38 (CD38) -directed therapy is permitted only if all the following are fulfilled:

• Best response achieved during CD38-directed therapy was = PR.

• Patient did not progress while receiving CD38-directed therapy or within 60 days of last dose of therapy.

• Patient did not discontinue CD38-directed therapy due to a related AE.

3. Prior treatment with carfilzomib is permitted only if all the following are fulfilled:

• Best response achieved during carfilzomib-based therapy was = PR.

• Patient did not progress while receiving carfilzomib-based therapy or within 60 days of last dose of therapy.

• Patient did not discontinue carfilzomib due to a related AE.

4. Creatinine Clearance (CrCl) =60 ml/min measured within 4 weeks of enrollment. CrCl can be measured or estimated using Cockcroft-Gault method, Modification of Diet in Renal Disease (MDRD), or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae.

5. Age = 18 years at the time of signing the informed consent documentation. Age limit of 75 years.

6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 within 4 weeks of enrollment (Appendix A).

7. Absolute neutrophil count (ANC) = 1.0 K cells/µL, hemoglobin = 8 g/dL, and platelet count = 50 K platelets/µL measured within 4 weeks of enrollment unless cytopenias are deemed to be due to disease at the discretion of the clinical Investigator. Transfusions and administration of growth factors are permissible.

8. Adequate hepatic function with bilirubin < 1.5 x the upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN measured within 4 weeks of enrollment.

9. All study participants must be able to tolerate one of the following thromboprophylactic strategies: oral factor Xa inhibitors or low molecular weight heparin or alternative anti-coagulant.

10. Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test within 10-14 days and again within 24 hours prior to prescribing of iberdomide for Cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective (barrier) method, at the same time at least 28 days before she starts taking iberdomide without interruption. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.

• A FCBP is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Females who do not meet the above definition of FCBP should be classified as females not of childbearing potential (FNCBP).

Exclusion Criteria:

1. Patients receiving concurrent systemic treatment for MM with the following exceptions:

• Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted.

• Patients may receive kyphoplasty/vertebroplasty for symptomatic vertebral compression fractures.

• Bone targeting agents are permitted.

• Concurrent or prior treatment with corticosteroids for indications other than MM is permitted.

• Focal radiation therapy within 14 days prior to randomization with the exception of palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma.

• Prior MM treatments must be concluded with a washout period of 2 weeks from last dose.

2. Patients who are refractory to an anti-CD38-directed regimen:

• Prior anti-CD38-directed therapy and carfilzomib are permitted as long as above inclusion criteria are met.

3. Patients with plasma cell leukemia.

4. Patients with Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes syndrome (POEMS syndrome).

5. Patients with amyloidosis.

6. Patients with known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal within 4 weeks of enrollment.

Note: FEV1 testing is required for patients suspected of having COPD, and patients must be excluded if FEV1 < 50% of predicted normal at any time during the study.

7. Pregnant or lactating females. Because there is a potential risk for AEs in nursing infants secondary to treatment of the mother with carfilzomib in combination with iberdomide, pregnant or lactating females are excluded from study participation. These potential risks may also apply to other agents used in this study.

8. Uncontrolled hypertension (ie, systolic blood pressure [BP] > 160 mmHg, diastolic BP > 100 mmHg) or diabetes

9. Patients with active hepatitis B or C infection.

10. Patient is:

• Seropositive for human immunodeficiency virus (HIV) (Section 10.3.5.1) within 4 weeks of enrollment.

• Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]) within 4 weeks of enrollment. Patients with resolved infection (i.e., patients who are HBsAg negative but positive for antibodies to hepatitis B core antigen (anti-HBc) and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (RT-PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Patients with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination do not need to be tested for HBV DNA by PCR.

• Seropositive for hepatitis C (except in the setting of a sustained virologic response (SVR), defined as aviremia at least 12 weeks after completion of antiviral therapy).

For more information regarding the timing and frequency of hepatitis testing, refer to Section 10.3.5.1.

11. Significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, symptomatic ischemia, current uncontrolled arrhythmias, screening electrocardiogram (ECG) with corrected QT interval (QTc) of > 470 msec within 4 weeks of enrollment, pericardial disease, or myocardial infarction within 4 months prior to enrollment, and left ventricular ejection fraction (EF) < 40% as assessed by transthoracic echocardiogram (ECHO) within 4 weeks of enrollment. Current unstable angina as determined by history and physical exam, hypertrophic cardiomyopathy or restrictive cardiomyopathy

12. Pulmonary hypertension

13. Has refractory gastrointestinal (GI) disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption of oral agents

14. Uncontrolled intercurrent illness including but not limited to active infection or psychiatric illness/social situations that would compromise compliance with study requirements

15. Significant neuropathy = Grade 3 with pain at baseline

16. Contraindication to any concomitant medication, including antivirals or anticoagulation

17. Major surgery within 3 weeks prior to first dose

18. Prior treatment with iberdomide

19. For female patients: Patient plans to become pregnant or donate eggs during the Treatment Period and/or required period for contraception use post-last dose of study treatment.

20. For male patients: Patient plans to father a child or donate sperm during the Treatment Period and/or required period for contraception use post-last dose of study treatment.

21. Patients with limited decision-making capacity.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Refractory Multiple Myeloma
• Relapsed Multiple Myeloma

Intervention

Drug:
• Iberdomide
Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows: Combination therapy: Cycles 1 to 8: 1 mg per day*, Days 1 to 21 every 28 days. Monotherapy: Cycles 9 to 20: 1 mg per day*, Days 1 to 21 every 28 days. (*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy
• Carfilzomib
Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows: Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15 Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15.
• Daratumumab
Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows: Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22 Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15 Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1.
• Dexamethasone
Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows: Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22 Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15 Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15.
• Acetaminophen
Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows: Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22 Cycles 3 through 6: 650 mg/dose on Days 1 and 15 Cycles 7 and 8: 650 mg/dose on Day 1.
• Diphenhydramine
Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows: Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22 Cycles 3 through 6: 25 mg/dose on Days 1 and 15 Cycles 7 and 8: 25 mg/dose on Day 1.
• Montelukast
Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows: Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D).

Locations

Country	Name	City	State
United States	University of Miami	Miami	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Carl Ola Landgren, MD, PhD	Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of MRD-negativity: Iber-KDd Combination therapy.	The rate of minimal residual disease negativity (MRD-negativity) will be reported as the number of participants achieving MRD-negativity after eight cycles of Iber-KDd combination therapy. MRD-negativity is defined as less than one (<1) residual cancer cell detected in 100,000 cells assessed.	Up to 8 months
Secondary	Number of Participants Experiencing Treatment-Related Toxicity After Starting Iber-KDd Combination Therapy	The safety and tolerability of Iber-KDd combination therapy will be assessed and reported as the number of participants experiencing treatment-related toxicity after start of combination therapy, including treatment-related adverse events (AEs) and serious adverse events (SAEs). AEs and SAEs will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5, per physician discretion.	Up to 9 months
Secondary	Best Response: Iber-KDd Combination Therapy	Best response will be reported as the proportion of participants achieving their greatest response to Iber-KDd combination therapy as follows: Partial response (PR) or better, very good partial response (VGPR) or better, complete response (CR), and stringent complete response (sCR). Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 8 months
Secondary	Overall Response Rate (ORR): Iber-KDd Combination Therapy	Overall response rate (ORR) is defined as the number of participants achieving partial response (PR), very good partial response (VGFR)m complete response (CR) or stringent complete response (sCR) to Iber-KDd combination therapy. Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 8 months
Secondary	Best Response: Iber Monotherapy	Best response will be reported as the proportion of participants achieving their greatest response to Iberdomide monotherapy as follows: Partial response (PR) or better, very good partial response (VGPR) or better, complete response (CR), and stringent complete response (sCR). Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 20 months
Secondary	Overall Response Rate (ORR): Iber Monotherapy	Overall response rate (ORR) is defined as the number of participants achieving partial response (PR), very good partial response (VGFR)m complete response (CR) or stringent complete response (sCR) to Iberdomide monotherapy. Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 20 months
Secondary	Duration of Response (DOR): Iber-KDd Combination Therapy	Duration of Response (DOR) to Iber-KDd combination therapy will be assessed. Duration of response (DOR) is defined as time from response to progression of disease or death, whichever occurs first.	Up to 8 months
Secondary	Overall Survival (OS)	Overall survival (OS) is defined as the time from date of first dose of study treatment to death from any cause.	Up to 5 years
Secondary	Progression-Free Survival (PFS)	Progression-free survival (PFS) is defined as time from date of first dose of study treatment to time of progression or death, whichever occurs first.	Up to 5 years
Secondary	Event-Free Survival (EFS)	Event-free survival (EFS) is defined as time from date of first dose of study treatment until 1) toxicity requiring removal from study, 2) progression, or 3) death, whichever occurs first.	Up to 5 years
Secondary	Rate of Sustained MRD-negativity.	The rate of sustained minimal residual disease negativity (MRD-negativity) at the completion combination Iber-KDd therapy and 12 cycles of iberdomide monotherapy will be assessed. MRD-negativity is defined as less than one (<1) residual cancer cell detected in 100,000 cells assessed. The number of participants will sustained Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 20 months
Secondary	Rate of MRD-negativity: Iberdomide monotherapy.	The rate of MRD-negativity as best response will be assessed among participants completing Iberdomide monotherapy. The number of participants with MRD-negativity at the 10^-5 sensitivity will be reported. MRD-negativity is defined as less than one (<1) residual cancer cell detected in 100,000 cells assessed. Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 20 months
Secondary	Number of Participants Experiencing Treatment-Related Toxicity After Starting Iberdomide Monotherapy	The safety and tolerability of Iber monotherapy will be assessed and reported as the number of participants experiencing treatment-related toxicity after start of monotherapy, including treatment-related adverse events (AEs) and serious adverse events (SAEs). AEs and SAEs will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5, per physician discretion.	Up to 21 months